15
Participants
Start Date
August 31, 2010
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2026
irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.
Memorial Sloan Kettering Cancer Center, New York
Collaborators (1)
Genentech, Inc.
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER